비타민 D 요법 시장 : 투여 경로, 유형, 용도, 연령층, 유통 채널, 세계 예측(2024-2032년)

Vitamin D Therapy Market size is anticipated to register 11.4% CAGR between 2024 and 2032, driven by the increasing adoption and demand worldwide. There is a growing awareness among consumers and healthcare professionals about the essential role of vitamin D in maintaining overall health, including bone health, immune function, and cardiovascular health. As more research highlights the potential benefits of vitamin D supplementation in preventing chronic diseases, there has been significant introduction of supplements and therapies. For instance, in February 2024, Cadila Pharmaceuticals launched an aqueous formulation of cholecalciferol for the treatment of vitamin D deficiency for exhibiting superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to conventional oil-based formulations.

Rising geriatric population, particularly in developed regions like North America and Europe, is also fueling the market growth. Older adults are also susceptible to vitamin D deficiency on account of reduced skin synthesis and dietary intake, leading to an increased need for supplementation. Lifestyle changes, including indoor sedentary habits and limited sun exposure, across various age groups, will further drive the industry expansion.

The vitamin D therapy industry is divided into route of administration, type, application, age group, distribution channel, and region.

Based on type, the market value from the prescription drugs segment will witness notable CAGR through 2032 due to the rising recognition of vitamin D deficiency as a significant public health concern worldwide. Healthcare providers are increasingly prescribing vitamin D supplements as part of therapeutic interventions for patients with diagnosed deficiencies or at high risk of deficiency. Prescription-strength vitamin D formulations allow precise dosing tailored to individual patient needs for ensuring effective management of deficiency-related conditions, such as osteoporosis, hypocalcemia, and certain autoimmune disorders.

Vitamin D therapy market from the skin diseases application segment is slated to generate revenue during 2024-2032 owing to the essential role to improve skin health and immune function. Vitamin D helps in regulating the immune response and promoting skin cell growth and repair, making it particularly beneficial in the management of various skin conditions. Individuals with chronic skin diseases often have impaired vitamin D synthesis due to limited sun exposure or compromised skin barrier function, leading to the increased reliance on supplements to maintain optimal levels.

Asia Pacific vitamin D therapy industry will record decent growth rate through 2032. This is attributed to the increasing prevalence of vitamin D deficiency among the regional population due to factors, such as indoor lifestyles, limited sun exposure, and dietary habits. This has led to heightened awareness among healthcare professionals and consumers about the importance of vitamin D supplementation. The availability of a diverse range of vitamin D products, including fortified foods and supplements, tailored to regional dietary preferences and healthcare needs, is also driving the market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing awareness of vitamin D deficiency
    • 3.2.1.2 Increasing ageing population
    • 3.2.1.3 Availability of OTC drugs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with therapy
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Oral
• 5.3 Parenteral

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 OTC drugs
• 6.3 Prescription drugs

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Osteoporosis
• 7.3 Muscle weakness
• 7.4 Rickets
• 7.5 Autoimmune disorders
• 7.6 Skin diseases
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Geriatric
• 8.3 Adults
• 8.4 Children

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Alkem Laboratories Ltd.
• 11.3 Atrium Innovations
• 11.4 Biotics Research Corporation
• 11.5 Cadila Healthcare Ltd.
• 11.6 GlaxoSmithKline plc
• 11.7 Merck & Co. Inc.
• 11.8 Ortho Molecular Products
• 11.9 Pfizer, Inc.
• 11.10 Sanofi